Introduction {#Sec1}
============

Familial adenomatous polyposis (FAP) is an autosomal dominant disorder caused by germline mutations in the Adenomatous Polyposis Coli (APC). There are multiple extraintestinal manifestations that follow a genotype-phenotype pattern \[[@CR1]\]; however, few data characterize the cognitive abilities of individuals with FAP. The APC protein has a major function in the development of the central nervous system, including a pivotal role in the development of the pre-post synaptic complex seen in *in-vivo* \[[@CR2]\] and animal studies \[[@CR3]\]. Moreover, high concentrations of the APC protein are present in the hippocampus, thalamus, and limbic system. Consequently, specific difficulties in the neurocognitive domains of attention, memory, and executive functions among individuals with deficient APC protein function might be expected.

Despite these known linkages few empirical findings examining the relationship between the expression of the APC protein and neurocognitive and behavioral functioning in individuals with APC mutations exist \[[@CR4]--[@CR7]\]. To date, animal studies have associated APC dysfunction with altered synaptic function in APC cKO mice, which plays a critical role in learning and memory \[[@CR8]\]. The genetic changes in APC that have been implicated in learning and memory deficits, repetitive behaviors, and reduced social interest \[[@CR8]\], also have been associated with working memory deficits, increased locomotion, and anxiety-related behavior \[[@CR3]\]. Though frequently hypothesized that genetic factors play an important role in psychiatric disorders, identification of specific genes has been a difficult task. Interestingly, preliminary findings implicate the APC gene in psychiatric disorders such as schizophrenia \[[@CR9], [@CR10]\] and depression \[[@CR11]\]. These psychiatric conditions have also been related to cognitive and behavioral impairments.

The primary aims of this exploratory study were to determine: (1) whether patients with FAP would evidence differences in performance on measures of neurocognitive function compared with non-affected controls; and (2) if neurocognitive manifestations followed a genotype-phenotype distribution as seen with other clinical manifestations in FAP. *Given the major role of the APC protein in the development of the central nervous system*, including the development of the pre-post synaptic complex seen in *in vitro* \[[@CR2], [@CR12]\] and *in vivo* \[[@CR8]\] studies, we hypothesized that individuals with FAP would show lower cognitive functioning compared to non-FAP controls across all ages. Given the potential for synaptic dysfunction, we would expect tasks related to processing speed and cognitive efficiency to be the most affected.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Sample size calculations were based on data from O'Malley et al. \[[@CR13]\] who reported a lower Verbal IQ for individuals with FAP compared to historical average scores. Using the Batería III Woodcock-Muñoz, with a mean IQ = 100 (SD = 15) a sample size of 23 in each group will have 90% power to detect a probability of 0.240 (effect size) that an observation in Group 1 is less than an observation in Group 2 using a Wilcoxon (Mann-Whitney) rank-sum test with a 0.050 two-sided significance level. Participants for both groups (ages ≥10 years) were ascertained via the Puerto Rico Familial Colorectal Cancer Registry (<http://purificar.rcm.upr.edu/index_eng.html>).

Inclusion criteria for cases included genetically confirmed FAP (based on a mutation on the APC gene performed by commercial laboratory testing), age ≥ 10 years, able to assent (children) and consent (adults) to participate in this study, and able to complete all neurocognitive testing. Inclusion criteria for controls included no known family history of FAP, negative clinical diagnosis of FAP based on colonoscopy (for adults), and willingness to undergo neurocognitive testing. Participants were all Spanish-speaking individuals from Puerto Rico. As education and age are correlated with IQ, cases were matched to non-FAP control individuals with regards to age (± three years), gender, and education (less than high school, at least high school, bachelors-degree or post-graduate education). Exclusion criteria for both cases and controls included previous diagnosis of any major psychiatric condition given the potential impact of these conditions on neurocognitive functioning, inability to sign/assent/consent study participation, or complete the neurocognitive tests.

Participants signed informed consent (or assent for children) prior to participation in the study and were evaluated at the Puerto Rico Clinical and Translational Research Consortium at the University of Puerto Rico (UPR) Medical Sciences Campus. The research protocol was approved by the Institutional Review Board of the UPR Medical Sciences Campus.

### Measures and procedures {#Sec4}

Neurocognitive procedures were carried out by licensed psychologists with extensive expertise in evaluation of neurocognitive disorders in children with genetic conditions. Selection of measures for this study was based on the following criteria: (1) tests have hypothesized links to brain regions where there are known high concentrations of APC protein; (2) age-appropriateness, with tasks going across the lifespan; (3) well established standardization and age-based normative data; and (4) strong psychometric properties. These outcome measures included the Test of Nonverbal Intelligence-4, the Batería III Woodcock-Mũnoz, and the Behavior Rating Inventory of Executive Functions-Adult. Measures of anxiety (General Anxiety Disorder Questionnaire-7), social communication (Social Communication Questionnaire), and depression (Patient Health Questionnaire-9) were used as potential covariates.

#### Batería III Woodcock-Mũnoz {#FPar1}

We used the cognitive components of this battery, which was translated and adapted from the publisher of the Woodcock-Johnson III Cognitive Battery via a calibration sample of approximately 1400 individuals from both the United States and several Spanish speaking countries including Puerto Rico. This battery is based on the Cattell-Horn-Carroll model of cognitive abilities and includes measures of comprehension-knowledge, visual-spatial thinking, auditory processing, processing speed, short-term memory, long-term memory, working memory, broad attention, and executive processes. This measure retains a high degree of technical adequacy with reliability for all of the clusters being ≥0.90 across all of the age ranges.

#### Test of nonverbal intelligence (TONI-4) {#FPar2}

Although the Batería III Woodcock-Mũnoz can generate a General Intellectual Factor, its use as a covariate in any of our analyses will confound group findings from the cognitive clusters as the intellectual estimate contains many of the same subtests. In that regard, for our overall measure of intellectual functioning, we have included a nonverbal measure of intellectual functioning: the TONI-4. While hoping to utilize the KBIT-2 to replicate the findings of O'Malley et al. \[[@CR13]\] there is no Spanish version of this test; consequently, using the TONI-4 provides a broader application for our sample and serves as a subject descriptive variable and as a potential covariate in the data analyses. The TONI-4 measures the ability to solve problems without overtly using language or complex motor responses, requiring the person to apply reasoning strategies to a problem defined by novel abstract figures. It includes verbal directions in Spanish, and responses require only simple pointing or gestures. The psychometric properties and normative basis of the TONI-4 are strong.

#### Behavior rating inventory of executive functions (BRIEF)-parent and adult versions {#FPar3}

The BRIEF is a behavior rating scale of executive functions in everyday life that is completed by the parent (up to age 18 years) or an individual (ages 18 and older). The BRIEF provides ecological measures of a variety of executive functions that address regulatory activities in day-to-day functioning. It comprises specific clinical scales (e.g., Organization, Shift, Working Memory, etc.) and three summary scales: Behavioral Regulation Index, Metacognition Index, and Global Executive Composite. Each version of the scale is standardized, well normed, has strong psychometric properties, and is available in both English and Spanish.

#### Patient health questionnaire (PHQ9) {#FPar4}

The PHQ9 is a nine-item depression scale completed by the individual. It is a multiple-choice [self-report inventory](https://en.wikipedia.org/wiki/Self-report_inventory) used as a [screening](https://en.wikipedia.org/wiki/Screening_(medicine)) and diagnostic tool for depression, anxiety, alcohol, eating, and somatoform conditions.

#### Generalized anxiety disorder (GAD-7) {#FPar5}

The GAD-7 is a self-reported questionnaire for screening and severity of generalized anxiety disorder. The GAD-7 has seven items, which measure severity of various signs of generalized anxiety disorder according to reported response categories with assigned points.

### Neurological exam {#Sec5}

All patients underwent a full neurologic examination exam performed by a neurologist that included a screening for mental status, apraxia, agnosia, aphasia, cranial nerve status, motor and sensory intactness, motor coordination, and deep tendon and corticospinal tract reflexes.

### Data analyses {#Sec6}

Preliminary data analyses included a comparison of selected sociodemographic characteristics by study group (FAP vs. Control) using χ^2^ test or Fisher's exact test. The anxiety and depression scores were compared by study group (FAP vs. Control) using t-tests or Wilcoxon rank-sum test. To address group differences in neurocognition, simple and multiple linear regression models were used to estimate the unadjusted and adjusted beta (B) coefficients with their 95% confidence intervals. The models were adjusted by age, gender, and educational level. *P*-values were corrected using the Bonferroni-Holm method (<https://www.statisticshowto.datasciencecentral.com/holm-bonferroni-method/>). To establish significance, observed *p*-values were compared with corrected *p*-values. If (1) observed *p*-values were lower than corrected *p*-values, and (2) there was an intersection between the significant *p*-values across the tests for each measure, then, neurocognitive measure was established to be significant.

For the evaluation of neurocognitive function status across the APC gene mutation spectrum, FAP patients were stratified according to location of mutations in the gene. Specifically, genotype-phenotype analysis was performed comparing individuals with mutations in codons within the attenuated-FAP region (codons \< 1000 and \> 1500; *N* = 9) and those within the mutation cluster region (between codons 1000 to 1500; *N* = 17). To determine the effect of the FAP genotype-phenotype, we used simple linear regression models and adjusted linear regression models with 95% confidence intervals. The models were adjusted by age, gender, and educational attainment. Statistical analyses were performed using Stata 14.0.

Results {#Sec7}
=======

Baseline demographic and clinical characteristics {#Sec8}
-------------------------------------------------

Baseline demographic characteristics are presented in Table [1](#Tab1){ref-type="table"}. Study participants (cases and controls) were equivalent with regards to age (mean age 34.2 ± 15.0 vs. 32.7 ± 13.8, *p* = 0.59), gender (*p* = 0.68), and educational level (*p* = 0.10), with both groups being unremarkable in the reporting of their symptoms. There were no statistically significant differences between patients with FAP and controls with regard to baseline anxiety (*p* = 0.21) and depression (*p* = 0.09) (data not shown). Table 1Baseline demographic characteristics of study participantsCharacteristicFAP group (*n* = 26)Control group (*n* = 25)*p*-value\*Age0.59  \< 21 years8 (30.8)6 (24.0)  ≥ 21 years18 (69.2)19 (76.0) Mean ± SD34.2 ± 15.032.7 ± 13.8Gender0.68 Male14 (53.9)12 (48.0) Female12 (46.2)13 (52.0)Medical insurance0.28 None1 (4.2)2 (8.3) Private13 (54.1)17 (70.8) Public10 (41.7)5 (20.8)Educational level0.09  \< 124 (15.4)9 (36.0)  ≥ 1222 (84.6)16 (64.0)Grade repetitions0.45 No15 (57.7)17 (68.0) Yes11 (42.3)8 (32.0)\**p*-value from the χ^2^ test or Fisher's exact test

Intelligence {#Sec9}
------------

Group differences on the TONI-4, our measure of Intelligence, are presented in Table [2](#Tab2){ref-type="table"}. Both FAP cases and controls fell within the average range of functioning, although the FAP patients had statistically significantly lower functioning compared with age-, gender- and education-matched controls (90.5 ± 5.6 vs. 95.6 ± 6.8, *p* = 0.008). Table 2Comparison of the FAP and control groups on the neurocognitive functionsMeasureFAP group\
(n = 26)Control group (n = 25)*p*-value\*Simple LRM\
(coefficients)*p*-valueAdjusted multivariate LRM\*\* (coefficients)*p*-valueAdjusted multivariate LRM\*\*\*\
(coefficients)*p*-valueMeanSDMeanSDTONI-4 IQ90.55.695.66.80.005−5.10.005−5.20.005−5.00.008Batería III clusters Verbal ability^\#^88.27.795.77.80.001−7.50.001−7.40.001−7.20.002 Thinking ability^\#^80.510.597.810.3\< 0.0001−17.3\< 0.0001−16.7\< 0.0001− 16.9\< 0.0001 Cognitive efficiency^\#^81.111.994.79.90.0001−13.6\< 0.0001− 13.4\< 0.0001− 13.3\< 0.0001 Long-term memory^\#^66.814.385.112.1\< 0.0001−18.3\< 0.0001−17.8\< 0.0001− 18.3\< 0.0001 Processing speed^\#^85.114.7102.09.7\< 0.0001−16.9\< 0.0001− 16.6\< 0.0001− 17.2\< 0.0001 Phonemic awareness88.610.897.68.70.002−8.90.002−8.70.002−8.50.004 Working memory^\#^84.410.795.611.40.0007− 11.10.001− 11.20.001−11.20.001 Cognitive fluency^\#^78.312.291.89.90.0001−13.5\< 0.0001− 13.5\< 0.0001− 14.8\< 0.0001 Executive processes^\#^83.813.7100.89.7\< 0.0001−17.0\< 0.0001− 17.0\< 0.0001− 17.1\< 0.0001BRIEF-Adult Inhibit49.37.947.17.00.3192.30.3192.40.3052.00.385 Shift51.810.348.911.90.2562.90.3913.20.3912.90.396 Emotional control51.58.647.710.20.0673.90.1804.00.1623.60.225 Self-monitor49.58.646.49.80.2123.10.2703.20.2513.10.291 Initiate50.510.949.29.40.7951.30.6771.50.6261.50.642 Working memory53.711.549.48.90.2184.30.1784.60.1124.40.180 Plan/Organize50.310.949.013.90.5871.30.7311.70.6221.10.772 Task monitor51.511.548.78.70.5712.80.3723.20.2402.40.452 Organization of materials49.88.250.38.70.870−0.40.870−0.20.929−0.70.779 Behavior regulation index50.88.847.610.50.2663.30.2663.50.2143.30.278 Metacognitive index51.110.849.29.80.5951.90.5492.20.4411.70.589 Global executive composite51.110.048.310.10.2722.80.3563.10.2642.70.389\**p*-values from the T-test or Wilcoxon rank-sum (Mann-Whitney) test; \*\*Adjusted by age and gender; \*\*\*Adjusted by education. *LRM* Linear Regression Models. ^\#^Neurocognitive measures are significant under the Bonferroni-Holmes corrections for all the statistical tests simultaneously

Neurocognitive functioning {#Sec10}
--------------------------

### Batería-III summary scores {#FPar6}

Findings of the groups on the Batería-III summary scores are shown in Table [2](#Tab2){ref-type="table"}. Across all of the Batería-III summary scores, FAP cases reflected *significantly* more risk for cognitive dysfunction than the controls, with the cases showing performances in the lower quartile on Verbal Ability, Thinking Ability, Cognitive Efficiency, Long-Term Retrieval, Processing Speed, Phonemic Awareness, Working Memory, Cognitive Fluency, and Executive Processes. In particular, FAP cases scored within the deficient range for Long-Term Retrieval and Cognitive Fluency.

Specific group comparisons on the obtained scores revealed a similar pattern of findings wherein the FAP Group performed significantly lower than controls on: Verbal Ability (LRM − 7.2, *p* = 0.002); Thinking Ability (LRM − 16.9, *p* \< 0.0001; Cognitive Efficiency (LRM − 13.3, p \< 0.0001); Long-Term Memory (LRM − 18.3, p \< 0.0001); Processing Speed (LRM − 17.2, p \< 0.0001; Phonemic Awareness (LRM − 8.5, *p* = 0.004); Working Memory (LRM − 11.2, *p* = 0.001); Cognitive Fluency (LRM − 14.8, p \< 0.0001); and Executive Processes (LRM − 17.1, p \< 0.0001).

### Batería-III subtests {#FPar7}

An exploratory examination of group differences on the Batería-III subtests was conducted to determine if any of the subtests were influential in the summary score findings. Specifically, 13 of the 15 subtests produced significant group differences, with FAP cases performing below controls on each of these 13 subtests. Effect sizes were in the large range in every instance. After Bonferonni Correction (i.e., *p* \< 0.003), nine of the Batería-III subtests remained statistically significant including: Verbal Comprehension, Visual-Auditory Learning, Spatial Relations, Sound Blending, Concept Formation, Visual Matching, Auditory Working Memory, Retrieval Fluency, and Decision Speed.

Group differences in ratings of executive functions {#Sec11}
---------------------------------------------------

We only had five cases where parents and child needed to complete the BRIEF, and all fell within the average range. Consequently, given the small sample size, no further analysis was conducted (data not shown). For the Adult BRIEF, both cases and controls rated their executive functioning to be within the average range. Group comparisons (FAP cases vs. controls) did not show any significant differences on any of the individual or summary scales of the BRIEF-Adult (Table [2](#Tab2){ref-type="table"}).

Genotype-phenotype correlation analysis {#Sec12}
---------------------------------------

Neurocognitive status was analyzed according to APC mutation location (Table [3](#Tab3){ref-type="table"}). FAP cases were grouped in two categories based on APC gene mutations: attenuated FAP (mutations in codons \< 1000 and \> 1500; *N* = 9) and classic FAP, those with an APC gene mutation in the mutation cluster region (between codons 1000 to 1500; *N* = 17). The two groups did not differ on age or gender (*p* \> 0.05), respectively (data not shown). Findings revealed that the two FAP groups were not significantly different on IQ (*p* = 0.709). However, FAP cases with mutations located within the classic mutation cluster had marginally lower performance on Woodcock-Muñoz summary scores of Cognitive Efficiency (*p* = 0.076) and Processing Speed, (*p* = 0.056), and on BRIEF-Adult scales of Shift (*p* = 0.058) and Initiate (*p* = 0.081) compared to FAP cases with mutations in the attenuated FAP region (Table [3](#Tab3){ref-type="table"}). Table 3Comparisons of FAP Severity Groups on Neurocognitive FunctionsMeasureAttenuated FAP Group (*n* = 9)Classic FAP Group (*n* = 17)*p*-value\*Simple LRM(coefficients)*p*-valueAdjusted multivariate LRM\*\* (coefficients)*p*-valueAdjusted multivariate LRM\*\*\* (coefficients)*p*-valueMeanSDMeanSDTONI-4 IQ91.24.590.26.30.662−1.00.662−1.00.670−0.90.709Batería III clusters Verbal ability89.75.587.48.70.479−2.30.479−2.30.504−2.00.566 Thinking ability81.810.079.910.90.669−1.90.669−2.00.671−1.80.704 Cognitive efficiency87.26.477.813.00.054−9.40.054−9.40.064−9.20.076 Long-term memory65.016.267.713.60.6552.70.6552.40.6772.60.666 Processing speed92.97.981.016.00.048−11.90.048−12.10.045−11.40.056 Phonemic awareness91.111.187.310.70.400−3.80.400−3.80.419−4.20.379 Working memory88.66.682.211.90.154−6.30.154−6.20.168−6.10.189 Cognitive fluency82.411.076.112.50.210−6.40.210−6.50.164−6.20.193 Executive processes84.810.883.215.30.791−1.50.791−1.60.781−1.00.862BRIEF-Adult Inhibit50.45.948.88.80.657−1.60.657−1.30.712−0.50.886 Shift57.18.149.110.40.052−8.10.068−7.60.055−7.90.058 Emotional control52.56.151.09.80.519−1.50.696−1.20.742−1.30.726 Self-monitor52.49.348.98.10.229−4.40.249−4.00.253−5.20.134 Initiate55.812.247.99.50.070−7.90.095−7.40.082−7.90.081 Working memory52.912.654.111.40.7351.20.8181.80.6631.30.760 Plan/Organize54.312.348.39.90.176−5.90.214−5.30.158−5.50.162 Task monitor54.810.949.911.80.310−4.80.345−4.10.287−3.60.369 Organization of materials50.88.649.48.20.706−1.40.706−1.10.744−0.50.882 Behavior regulation index53.66.749.49.60.281−4.20.281−3.70.270−3.80.283 Metacognitive index53.911.549.710.50.443−4.20.380−3.60.344−3.60.361 Global executive composite54.19.249.610.20.297−4.60.300−4.00.253−4.00.276\**p*-values from T-test or Wilcoxon rank-sum (Mann-Whitney) test; \*\*Adjusted by age and gender; \*\*\*Adjusted by age, gender and education

Neurological examination {#Sec13}
------------------------

A full neurologic examination was performed in all 26 cases and in 24 controls. No consistent pattern of abnormalities was observed in the cases or control subjects. Four cases showed findings consistent with a mild distal sensory neuropathy, in three of the cases this was related to prior chemotherapy for colon cancer.

Discussion {#Sec14}
==========

The findings of this study provide a proof-of-concept for an important role of the APC protein in neurocognitive function. Moreover, this investigation is the first to systematically evaluate neurocognition in the FAP population using a carefully matched case-control design, and evaluating important potential confounders such as anxiety, depression, and level of education. Our findings reflected significantly lower performance on IQ and in a variety of neurocognitive functions, with effect sizes being within the large range. Furthermore, for many of the specific neurocognitive functions, individuals with FAP performed in the bottom quartile, suggesting possible difficulties in these areas. Interestingly, there were no group differences noted on the adult self-ratings (BRIEF questionnaire) of executive functions, perhaps secondary to self-perceptions not recognizing the subtle differences that might be present when compared to their peers.

Original observations describing intellectual disabilities among individuals with FAP were limited to case reports \[[@CR4], [@CR5], [@CR7]\]. Patients with FAP were shown to perform lower on test of intellectual capacity, particularly on verbal tasks, when compared to patients with ulcerative colitis \[[@CR14]\]. In addition, a conference presentation by O'Malley et al. \[[@CR13]\] directly examined the cognitive functioning of individuals with FAP by conducting a brief intelligence test with 44 adult subjects from 42 families. They found that the group performed in the average IQ range, with 27% of the sample performing in the bottom quartile. Verbal abilities were significantly lower than average, although not impaired (Verbal IQ = 95.5 ± 12), with the majority of participants having their verbal abilities significantly lower than their nonverbal abilities (*p* = 0.020). Our nonverval abilities were similar in the level to that obtained by O'Malley et al. The authors hypothesize that the APC protein was critical for dependent pathways in the cochlea and could have a role in (verbal) cognition. In contrast, our investigation is the first to incorporate an age-, gender-, and education-matched control group with a complete battery of neurocognitive tests enabling interrogation of multiple domains and corresponding anatomical regions. Moreover, our scientific rationale differs from that of previous investigators as it relates to the *central role of the APC protein in the development of the synaptic complex* in the central nervous system \[[@CR2], [@CR3]\].

The APC protein has multiple domains and binding patterns, which indicates a multi-functional nature \[[@CR15]\]. The classic colorectal adenomatous polyposis seen in patients with FAP results from the known negative regulation of APC protein in the *Wnt* transcription pathway \[[@CR16]\]. The APC protein also carries out microtubule-organizing functions in neurons \[[@CR17]--[@CR19]\], and has a role in synapse assembly \[[@CR20]\]. The APC protein is found in many cell types including neurons in the adult rodent brain \[[@CR21]\], and high levels of expression of the APC mRNA are observed during brain development \[[@CR22], [@CR23]\]. Moreover, APC protein functions in localizing nicotinic acetylcholine receptors (nAChRs) at neuronal synapses *in vivo* \[[@CR24]\] organizing a multi-molecular complex that stabilizes the local cytoskeleton and links the alpha-3nAChRs subunit to APC at postsynaptic sites \[[@CR2]\]. This complex of proteins is required for coordinating presynaptic and postsynaptic maturation in cholinoceptive neurons in vertebrate animals \[[@CR24]\]. This complex is vital in processing information as nicotinic receptors have a key role in attention, learning, and memory and are highly concentrated in the cerebral cortex, hippocampus, thalamus and limbic system \[[@CR25]\]. Thus, truncated or absence of the APC protein in the brain among patients with FAP may result in altered neurocognitive functions including attention deficits and learning impairments, and our findings provide preliminary support for these assertions. Given the pathophysiology inherent in these processes, we had hypothesized that patients with FAP would show lower processing speed and cognitive efficiency than controls and, in fact, this is what was uncovered. This was in addition to a significant lower performance than controls in a host of other neurocognitive domains.

In an elegant study using a conditional APC knockout mouse with deletion targeted predominantly to forebrain excitatory neurons (hippocampus and cortex), Mohn et al. reported impaired hippocampal-dependent spatial learning \[[@CR8]\]. APC knock-out mice had double the latency to goal, committing three times as many errors, and took less efficient routes to the goal compared to wild-type mice \[[@CR8]\]. In this in vivo model, APC loss lead to excessive B-catenin and *Wnt* signal transduction in the forebrain as well as cognitive impairments and an autistic-like presentation \[[@CR8]\]. Similarly, Koshimizu et al. had reported that the APC gene plays a role in locomotion and working memory performance. These investigators reported decreased locomotor activity and age-dependent working memory deficits using a heterozygous APC knockout mice model \[[@CR26]\]. Hence, our clinical observations of significantly lower performance on IQ and a variety of specific neurocognitive functions among patients with FAP as compared to controls may result from defective APC protein in the synaptic complex in the central nervous system.

Most mutations found in patients with FAP represent truncating mutations of the APC gene \[[@CR1]\] and clinical presentations typically follow a genotype-phenotype pattern although there are known exceptions \[[@CR27], [@CR28]\]. For instance, severe colorectal polyposis (\> 1000 adenomas) correlates with mutations between codons 1250 and 1464 \[[@CR29]\], while desmoid tumors may be more prevalent in persons with mutations after codon 1444 \[[@CR30], [@CR31]\]. In our current study, we examined neurocognitive functions across two genetically defined subgroups including individuals with attenuated-FAP and those with classic FAP as defined by the location of their *APC* mutations. The location of the mutation in the APC gene correlates with the length and function of the APC protein, with less function seen among those with mutations in the classic FAP region. Our exploratory analysis suggests differences in several categories including cognitive efficiency and processing speed, and selected executive functions (set shifting, initiation) with higher performance among patients with attenuated-FAP compared to those with classic FAP.

Evidence for a potential etiologic role of APC protein in neurodevelopmental disorders arises from human studies examining the association of APC gene polymorphisms and autism spectrum disorders \[[@CR32]\]. Neurodevelopmental disorders such as autism spectrum disorder, bipolar disorder and schizophrenia may result from dysregulation of *Wnt* signaling \[[@CR33]\], which is also seen in patients with FAP. Furthermore, deletions of the APC gene and occurrence of adenomatous polyposis have been reported in patients originally referred for autism \[[@CR34]\]. In our Polyposis Registry \[[@CR1]\], we have several patients with either mutations and/or deletion of the APC gene who are also diagnosed with autism spectrum disorder. The APC gene has also been claimed to be associated with susceptibility to schizophrenia \[[@CR10]\], providing an additional line of evidence for the important role that APC protein may have in the etiology of neurodevelopmental disorders. Our study provides proof-of-concept and preliminary clinical data of the ubiquitous deficit in neurocognitive functions associated with mutations in the APC gene in a genetically defined syndrome.

The pervasive nature of the observed cognitive dysfunction suggests that loss or dysfunction of the APC protein occurs across the cerebral cortex. Moreover, the observed neurocognitive dysfunction followed a genotype-phenotype correlation as occurs with other clinical manifestations in FAP patients. However, as FAP is a chronic debilitating disease that impacts individuals from early adolescence it may negatively affect cognition by altering educational milestones due to medical/surgical management of the condition. We thus reviewed and contrasted the effect on neurocognitive outcomes in two well characterized genetically-driven chronic illnesses, Cystic Fibrosis and Sickle Cell Anemia \[[@CR35]--[@CR37]\]. Results of these studies showed that children with Cystic Fibrosis had general intelligence levels that were comparable to the general population of the same age group \[[@CR36]\]. Furthermore, a study on psychological assessment in adults with Cystic Fibrosis could not detect an increase in depressive or anxiety related symptoms in the affected adults \[[@CR38]\]. In contrast, studies on the neurocognitive effects in children and adolescents with Sickle Cell Anemia reported learning difficulties \[[@CR37]\], need for special education supports \[[@CR37]\], lower visual-motor abilities \[[@CR39]\], and decreased verbal short-term memory \[[@CR35]\]. These neurocognitive effects were associated with the severity of the Sickle Cell Anemia, which suggest the mechanism for the neurocognitive deficits observed is reduced oxygen delivery rather than other confounding social determinants \[[@CR35], [@CR37]\]. The mechanism by which APC mutations cause neurocognitive dysfunction results from the major role of the APC protein in the development of the pre-post synaptic complex \[[@CR2], [@CR3]\]. Thus, the mechanisms by which the neurocognitive deficits present in both illnesses (FAP vs. Sickle Cell Anemia) differ in etiology. Our study serves as a proof-of-concept for the potential role of APC protein in neurocognition among patients with FAP; however, our study could not fully account for the possible confounding effect on cognition of having a chronic condition, such as school absenteeism, frequent medical visits, among others.

It is also important to explore how patients with FAP might react to the results obtained in this pilot study, by examining the attitudes, emotional impact and perceptions of these individuals regarding their cognitive abilities. While we are clearly cognizant of this being yet another potential worry for patients with FAP and their families, early recognition of potential risk for cognitive difficulties might lay the foundation for earlier intervention and, perhaps, lessening or preventing such difficulties over the life course for individuals with FAP. Studies on the effects of other chronic illnesses affecting children and young adults are needed to fully elucidate if the neurocognitive effects seen in patients with FAP are partly due to a defective/truncated APC protein and not by other confounders. Our proof-of-concept findings would suggest that this is a viable path for further scientific inquiry.

Conclusion {#Sec15}
==========

Our study in a genetically defined hereditary syndrome provides preliminary clinical data supporting an important role of the APC protein in neurocognitive function and of the pervasive neurocognitive dysfunctions that may be associated with mutations in the APC gene. Validation of our current observations in larger ethnically diverse cohorts would support cognitive screening for individuals with FAP to establish therapeutic interventions early in life as done for other neurodevelopmental disorders. Hence, studies examining the role of the APC protein among individuals with other neurodevelopmental conditions that manifest cognitive impairment, such as autism spectrum disorders and schizophrenia \[[@CR40], [@CR41]\] are warranted.
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